Market Cap | 3.03B | P/E | - | EPS this Y | 5.30% | Ern Qtrly Grth | - |
Income | -38.68M | Forward P/E | -8.70 | EPS next Y | 1.90% | 50D Avg Chg | 14.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 23.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -9.00% |
Recommedations | 2.10 | Quick Ratio | 21.09 | Shares Outstanding | 126.05M | 52W Low Chg | 151.00% |
Insider Own | 27.94% | ROA | -19.57% | Shares Float | 71.47M | Beta | 1.31 |
Inst Own | 37.07% | ROE | -29.60% | Shares Shorted/Prior | 10.29M/10.47M | Price | 12.88 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 336,556 | Target Price | 4.67 |
Oper. Margin | - | Earnings Date | Nov 10 | Volume | 179,908 | Change | -1.53% |
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
JP Morgan | Neutral | Sep 30, 24 |
Guggenheim | Buy | Sep 10, 24 |
B of A Securities | Neutral | Sep 4, 24 |
Jefferies | Buy | Jun 10, 24 |
B of A Securities | Neutral | May 29, 24 |
B of A Securities | Neutral | Jan 2, 24 |
BTIG | Buy | Jul 25, 23 |
Jefferies | Buy | Dec 21, 22 |
Morgan Stanley | Equal-Weight | Nov 10, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Palihapitiya Chamath | - - | Nov 19 | Sell | 1.31 | 7,256,367 | 9,505,841 | 11/21/23 | |
Palihapitiya Chamath | 10% Owner 10% Owner | Nov 15 | Sell | 1.3 | 752,800 | 978,640 | 5,183,367 | 11/17/23 |
Palihapitiya Chamath | 10% Owner 10% Owner | Nov 09 | Sell | 1.59 | 576,700 | 916,953 | 5,936,167 | 11/14/23 |
Palihapitiya Chamath | 10% Owner 10% Owner | Nov 06 | Sell | 1.6 | 209,833 | 335,733 | 6,512,867 | 11/08/23 |
Palihapitiya Chamath | 10% Owner 10% Owner | Nov 01 | Sell | 1.69 | 405,400 | 685,126 | 6,722,700 | 11/03/23 |
Palihapitiya Chamath | 10% Owner 10% Owner | Oct 27 | Sell | 1.64 | 391,400 | 641,896 | 7,128,100 | 10/31/23 |
Palihapitiya Chamath | 10% Owner 10% Owner | Oct 24 | Sell | 1.77 | 321,473 | 569,007 | 7,519,500 | 10/26/23 |
Palihapitiya Chamath | 10% Owner 10% Owner | Oct 19 | Sell | 1.98 | 447,500 | 886,050 | 7,840,973 | 10/23/23 |
Palihapitiya Chamath | 10% Owner 10% Owner | Oct 16 | Sell | 2.66 | 447,043 | 1,189,134 | 8,288,473 | 10/18/23 |
Palihapitiya Chamath | 10% Owner 10% Owner | Oct 11 | Sell | 3.07 | 486,863 | 1,494,669 | 8,735,516 | 10/13/23 |
Palihapitiya Chamath | 10% Owner 10% Owner | Oct 05 | Sell | 4.45 | 277,621 | 1,235,413 | 9,222,379 | 10/10/23 |
Palihapitiya Chamath | 10% Owner 10% Owner | Sep 19 | Sell | 5.47 | 1,700,000 | 9,299,000 | 2,073,000 | 09/21/23 |
Cowen Aaron | 10% Owner 10% Owner | Sep 06 | Buy | 6.99 | 7,007 | 48,979 | 6,280,175 | 09/08/22 |
Cowen Aaron | 10% Owner 10% Owner | Aug 30 | Buy | 8.45 | 3,868 | 32,685 | 6,273,168 | 09/01/22 |